TRexBio, a San Francisco, CA-based biotechnology company decoding human tissue immune biology to create new therapeutics, raised $84M in Series B funding.
The round was led by Delos Capital with participation from Avego BioScience Capital, Agent Capital, Eli Lilly and Company, SV Health Investors, Pfizer Ventures, Johnson & Johnson, Alexandria Venture Investments, and Polaris Partners. In connection with the financing, Eric Huang, PhD, Partner at Delos; Joel S. Marcus, Executive Chairman & Founder at Alexandria Venture Investments; and Eric Pham, PhD, Managing Director at Avego have joined the company’s Board of Directors.
Led by CEO Johnston Erwin, TRexBio is a biotechnology company developing purpose-built therapeutics by leveraging computational biology tools, a focus on human tissue, and expertise in immunobiology. Its platform maps human tissue Treg behavior to disease processes to identify and characterize novel targets for therapeutic intervention.
Leveraging this platform, it is building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis.
The company intends to use the funds to advance its lead candidate, TRB-061, a purpose-engineered TNFR2 agonist, through early clinical proof of concept in patients with immune mediated diseases including atopic dermatitis and ulcerative colitis.
TRB-061 will be the second program from TRexBio to enter the clinic, following TRB-051 currently in Phase 1 with TRexBio collaboration partner Lilly.
FinSMEs
14/11/2024